

Application No. Not Yet Assigned
Paper Dated: January 12, 2004
In Reply to USPTO Correspondence of N/A
Attorney Docket No. 0470-050079


Customer No. 28289

AMENDMENTS TO THE ABSTRACT

After the claims, please insert a new Abstract Of The Disclosure, which is attached hereto as a separately typed page.

PHARMACEUTICAL COMPOSITION COMPRISING ESTETROL
DERIVATIVES FOR USE IN CANCER THERAPY

The present invention relates to a method of treating or preventing estrogen-sensitive tumours in a mammal, said method comprising the administration of a therapeutically effective amount of an estrogenic component to said mammal, wherein the estrogenic component is selected from the group consisting of:
substances represented by the following formula



in which formula R₁, R₂, R₃, R₄ independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; precursors capable of liberating a substance according to the aforementioned formula when used in the present method; and mixtures of one or more of the aforementioned substances and/or precursors.

The estrogenic component according to the invention does not have undesirable proliferative effects on breast and/or endometrial tissue and displays sufficient estrogenicity to prevent that its administration will lead to hypoestrogenism and/or climacteric complaints.